Our laboratory has demonstrated that the induction of epilepsy in the pilocarpine model of acquired epilepsy produces an essentially permanent neuronal plasticity change in the expression of the cannabinoid receptor (CB1), one of the most abundant G-Protein coupled receptors in brain. We have also shown that this novel neuronal plasticity change in CB1 expression in the epileptic animal causes a significant decrease in both seizure frequency and duration. Although cannabinoids have been shown to have anticonvulsant effects and have been advocated as possible alternative treatments for seizure disorders, there are no laboratory studies on repetitive use and withdraw! of cannabinoids in treating epileptic animals. Our pilot studies with statistical validation suggest that repetitive treatment of seizures with cannabinoids can worsen seizures. We will conduct the following specific aims:
AIM 1 :To test the hypothesis that repetitive constant and increasing dose cannabinoid administration that both initially block seizures to which tolerance develops and subsequent cannabinoid withdrawal will lead to an increase in seizure frequency and duration and even to status epilepticus (SE) in epileptic animals;
AIM 2 : To test the hypothesis that repetitive constant increasing dose cannabinoid administration that leads to the development of tolerance and withdraw! causes changes in the expression of the CB1 receptor in the brains of epileptic animals;
Aim 3 : To test the hypothesis that repetitive constant and increasing dose cannabinoid administration that leads to the development of tolerance and withdraw! causes changes in the CB1 receptor function as assessed by CB1 stimulated Gprotein activation in the brains of epileptic animals;
Aim 4 : To test the hypothesis that repetitive constant and increasing dose cannabinoid administration that leads to the development of tolerance and withdraw! causes changes in the CB1 receptor function as assessed by alteration of CB1 receptor binding characteristics. This study proposes to evaluate the consequences and basic mechanisms of repetitive cannabinoid use and withdraw! that simulate the recreational use and abuse of cannabinoids on seizure frequency and duration and on CB1 receptor expression and function in the well established pilocarpine rat model of epilepsy. This study will determine if repetitive cannabinoid administration and withdraw! in epileptic animals that simulates cannabinoid abuse in man can cause permanent worsening of seizure disorders and even death by SE.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA005274-20
Application #
7680157
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
20
Fiscal Year
2008
Total Cost
$89,509
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Bagdas, Deniz; Alkhlaif, Yasmin; Jackson, Asti et al. (2018) New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology 138:72-79
Jackson, Kia J; Muldoon, Pretal P; Walters, Carrie et al. (2016) Neuronal calcium/calmodulin-dependent protein kinase II mediates nicotine reward in the conditioned place preference test in mice. Behav Pharmacol 27:50-6
Nass, Sara R; Long, Jonathan Z; Schlosburg, Joel E et al. (2015) Endocannabinoid Catabolic Enzymes Play Differential Roles in Thermal Homeostasis in Response to Environmental or Immune Challenge. J Neuroimmune Pharmacol 10:364-70
Muldoon, P P; Chen, J; Harenza, J L et al. (2015) Inhibition of monoacylglycerol lipase reduces nicotine withdrawal. Br J Pharmacol 172:869-82
Poklis, Justin L; Devers, Kelly G; Arbefeville, Elise F et al. (2014) Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int 234:e14-20
Poklis, Justin L; Nanco, Carol R; Troendle, Michelle M et al. (2014) Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal 6:764-9
Ignatowska-Jankowska, B M; Ghosh, S; Crowe, M S et al. (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171:1392-407
Bagdas, Deniz; Muldoon, Pretal P; Zhu, Andy Z X et al. (2014) Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology 85:67-72
Wolf, Carl E; Goldstein, Ashley; Poklis, Justin L et al. (2014) Evaluation of an enzyme immunoassay for the detection of methadone metabolite EDDP [2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine] in urine. J Clin Lab Anal 28:136-40
Ramesh, Divya; Gamage, Thomas F; Vanuytsel, Tim et al. (2013) Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. Neuropsychopharmacology 38:1039-49

Showing the most recent 10 out of 106 publications